Can Fisher & Paykel Healthcare justify Nvidia-level premium amid tariff noise

Can Fisher & Paykel Healthcare justify Nvidia-level premium amid tariff noise
Fisher & Paykel Healthcare's Lewis Gradon addressed shareholders at the company's AGM. (Image: Jacques Steenkamp)
Stock & Trade
Most markets have them - market darlings which are treated as all but sacrosanct investments, whose shares are placed on a pedestal and priced far above multiples of their competitors. Overowned and overbought, with fundamentals that are rarely subject to strict scrutiny.Does Fisher & Paykel Healthcare fall into this camp?Get up to date fast. Join BusinessDesk's WhatsApp channel.Its shares trade 58 times trailing earnings – nosebleed territory – which puts it at a significant premium to other blue-chip medical technolog...

More Markets

NZ stocks retreat from record high, down 0.7%
Markets Market Close

NZ stocks retreat from record high, down 0.7%

The S&P/NZX 50 Index dropped 103.60 points, or 0.76%, to 13,467.26.

Jamie Gray 10 Oct 2025
Govt looks to put its Chorus investment on the block
Infrastructure

Govt looks to put its Chorus investment on the block

The finance minister said there's no policy reason for Govt to hold Chorus securities.

Rebecca Howard 10 Oct 2025
Latest cap raise values Sharesies at $750m
Markets

Latest cap raise values Sharesies at $750m

In its eighth raise since 2017, Sharesies values its shares at $205 apiece.

Pattrick Smellie 10 Oct 2025
Green Cross Health's prescription for growth
Markets Small Cap Wrap

Green Cross Health's prescription for growth

Medical group gets tentative approval to become a PHO, Savor, Paysauce, and more.